{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T22:46:29Z","timestamp":1775601989376,"version":"3.50.1"},"reference-count":34,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,22]],"date-time":"2023-06-22T00:00:00Z","timestamp":1687392000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["slas-discovery.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["SLAS Discovery"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.slasd.2023.06.002","type":"journal-article","created":{"date-parts":[[2023,6,25]],"date-time":"2023-06-25T10:27:27Z","timestamp":1687688847000},"page":"344-349","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Novel beta-glucocerebrosidase chaperone compounds identified from cell-based screening reduce pathologically accumulated glucosylsphingosine in iPS-derived neuronal cells"],"prefix":"10.1016","volume":"28","author":[{"given":"Yusuke","family":"Naito","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sou","family":"Sakamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuto","family":"Kojima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Misaki","family":"Homma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maiko","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4856-4465","authenticated-orcid":false,"given":"Hideki","family":"Matsui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.slasd.2023.06.002_bib0001","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1016\/j.febslet.2009.10.021","article-title":"Lysosomal degradation of membrane lipids","volume":"584","author":"Kolter","year":"2010","journal-title":"FEBS Lett"},{"issue":"77","key":"10.1016\/j.slasd.2023.06.002_bib0002","first-page":"273","article-title":"Gaucher disease: insights from a rare Mendelian disorder","volume":"14","author":"Sidransky","year":"2012","journal-title":"Discov Med"},{"issue":"9645","key":"10.1016\/j.slasd.2023.06.002_bib0003","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/S0140-6736(08)61522-6","article-title":"Phenotype, diagnosis, and treatment of Gaucher's disease","volume":"372","author":"Grabowski","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.slasd.2023.06.002_bib0004","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/1750-1172-9-51","article-title":"Cost-effectiveness of enzyme replacement therapy for type 1 Gaucher disease","volume":"9","author":"van Dussen","year":"2014","journal-title":"Orphanet J Rare Dis"},{"issue":"4","key":"10.1016\/j.slasd.2023.06.002_bib0005","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.cell.2007.10.018","article-title":"LIMP-2 is a receptor for lysosomal mannose-6-phosphate-independent targeting of beta-glucocerebrosidase","volume":"131","author":"Reczek","year":"2007","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.slasd.2023.06.002_bib0006","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1096\/fasebj.5.3.2001789","article-title":"Saposin proteins: structure, function, and role in human lysosomal storage disorders","volume":"5","author":"O'Brien","year":"1991","journal-title":"FASEB J"},{"issue":"1","key":"10.1016\/j.slasd.2023.06.002_bib0007","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.bcmd.2010.10.012","article-title":"Characterization of the ERAD process of the L444P mutant glucocerebrosidase variant","volume":"46","author":"Bendikov-Bar","year":"2011","journal-title":"Blood Cells Mol Dis"},{"issue":"16","key":"10.1016\/j.slasd.2023.06.002_bib0008","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1093\/hmg\/ddi240","article-title":"ER retention and degradation as the molecular basis underlying Gaucher disease heterogeneity","volume":"14","author":"Ron","year":"2005","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.slasd.2023.06.002_bib0009","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.694764","article-title":"Exploring the genotype-phenotype correlation in GBA-Parkinson disease: clinical aspects, biomarkers, and potential modifiers","volume":"12","author":"Menozzi","year":"2021","journal-title":"Front Neurol."},{"issue":"5","key":"10.1016\/j.slasd.2023.06.002_bib0010","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1002\/humu.20676","article-title":"Gaucher disease: mutation and polymorphism spectrum in the glucocerebrosidase gene (GBA)","volume":"29","author":"Hruska","year":"2008","journal-title":"Hum Mutat"},{"issue":"10","key":"10.1016\/j.slasd.2023.06.002_bib0011","doi-asserted-by":"crossref","first-page":"5436","DOI":"10.1002\/anie.202013890","article-title":"Novel beta-glucocerebrosidase activators that bind to a new pocket at a dimer interface and induce dimerization","volume":"60","author":"Benz","year":"2021","journal-title":"Angew Chem Int Ed Engl"},{"issue":"3","key":"10.1016\/j.slasd.2023.06.002_bib0012","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0119141","article-title":"Tool compounds robustly increase turnover of an artificial substrate by glucocerebrosidase in human brain lysates","volume":"10","author":"Berger","year":"2015","journal-title":"PLoS ONE"},{"issue":"2","key":"10.1016\/j.slasd.2023.06.002_bib0013","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1021\/cb100321m","article-title":"Ca2+ homeostasis modulation enhances the amenability of L444P glucosylcerebrosidase to proteostasis regulation in patient-derived fibroblasts","volume":"6","author":"Wang","year":"2011","journal-title":"ACS Chem Biol"},{"issue":"4","key":"10.1016\/j.slasd.2023.06.002_bib0014","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1021\/cb600187q","article-title":"Chemical chaperones and permissive temperatures alter localization of Gaucher disease associated glucocerebrosidase variants","volume":"1","author":"Sawkar","year":"2006","journal-title":"ACS Chem Biol"},{"issue":"35","key":"10.1016\/j.slasd.2023.06.002_bib0015","doi-asserted-by":"crossref","first-page":"23502","DOI":"10.1074\/jbc.M109.012393","article-title":"Identification and characterization of ambroxol as an enzyme enhancement agent for Gaucher disease","volume":"284","author":"Maegawa","year":"2009","journal-title":"J Biol Chem"},{"issue":"2","key":"10.1016\/j.slasd.2023.06.002_bib0016","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.bcmd.2012.10.007","article-title":"Ambroxol as a pharmacological chaperone for mutant glucocerebrosidase","volume":"50","author":"Bendikov-Bar","year":"2013","journal-title":"Blood Cells Mol Dis"},{"issue":"2","key":"10.1016\/j.slasd.2023.06.002_bib0017","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1136\/jmedgenet-2019-106132","article-title":"Pharmacologic properties of high-dose ambroxol in four patients with Gaucher disease and myoclonic epilepsy","volume":"57","author":"Kim","year":"2020","journal-title":"J Med Genet"},{"issue":"3","key":"10.1016\/j.slasd.2023.06.002_bib0018","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1002\/acn3.292","article-title":"Ambroxol chaperone therapy for neuronopathic Gaucher disease: a pilot study","volume":"3","author":"Narita","year":"2016","journal-title":"Ann Clin Transl Neurol"},{"issue":"12","key":"10.1016\/j.slasd.2023.06.002_bib0019","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1038\/nchembio.466","article-title":"Ultrasensitive in situ visualization of active glucocerebrosidase molecules","volume":"6","author":"Witte","year":"2010","journal-title":"Nat Chem Biol"},{"issue":"3","key":"10.1016\/j.slasd.2023.06.002_bib0020","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1021\/ja5106738","article-title":"Fluorescence-quenched substrates for live cell imaging of human glucocerebrosidase activity","volume":"137","author":"Yadav","year":"2015","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.slasd.2023.06.002_bib0021","doi-asserted-by":"crossref","first-page":"31380","DOI":"10.1038\/srep31380","article-title":"Parkinson disease-linked GBA mutation effects reversed by molecular chaperones in human cell and fly models","volume":"6","author":"Sanchez-Martinez","year":"2016","journal-title":"Sci Rep"},{"issue":"7","key":"10.1016\/j.slasd.2023.06.002_bib0022","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1111\/j.1742-4658.2010.07588.x","article-title":"The pharmacological chaperone isofagomine increases the activity of the Gaucher disease L444P mutant form of beta-glucosidase","volume":"277","author":"Khanna","year":"2010","journal-title":"FEBS J"},{"issue":"37","key":"10.1016\/j.slasd.2023.06.002_bib0023","doi-asserted-by":"crossref","first-page":"13813","DOI":"10.1073\/pnas.0605928103","article-title":"The iminosugar isofagomine increases the activity of N370S mutant acid beta-glucosidase in Gaucher fibroblasts by several mechanisms","volume":"103","author":"Steet","year":"2006","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"4","key":"10.1016\/j.slasd.2023.06.002_bib0024","doi-asserted-by":"crossref","first-page":"e19037","DOI":"10.1371\/journal.pone.0019037","article-title":"Isofagomine in vivo effects in a neuronopathic Gaucher disease mouse","volume":"6","author":"Sun","year":"2011","journal-title":"PLoS ONE"},{"issue":"40","key":"10.1016\/j.slasd.2023.06.002_bib0025","doi-asserted-by":"crossref","first-page":"11696","DOI":"10.1002\/anie.201505147","article-title":"pH-Responsive Pharmacological Chaperones for Rescuing Mutant Glycosidases","volume":"54","author":"Mena-Barragan","year":"2015","journal-title":"Angew Chem Int Ed Engl"},{"issue":"16","key":"10.1016\/j.slasd.2023.06.002_bib0026","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.1002\/cbic.200800249","article-title":"Isofagomine induced stabilization of glucocerebrosidase","volume":"9","author":"Kornhaber","year":"2008","journal-title":"Chembiochem"},{"issue":"18","key":"10.1016\/j.slasd.2023.06.002_bib0027","doi-asserted-by":"crossref","first-page":"5914","DOI":"10.1021\/jacs.7b13003","article-title":"Beta-glucocerebrosidase modulators promote dimerization of beta-glucocerebrosidase and reveal an allosteric binding site","volume":"140","author":"Zheng","year":"2018","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.slasd.2023.06.002_bib0028","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.ebiom.2016.10.010","article-title":"Progranulin Recruits HSP70 to beta-glucocerebrosidase and is therapeutic against gaucher disease","volume":"13","author":"Jian","year":"2016","journal-title":"EBioMedicine"},{"issue":"1","key":"10.1016\/j.slasd.2023.06.002_bib0029","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1038\/s41598-018-19479-8","article-title":"Effects of ambroxol on the autophagy-lysosome pathway and mitochondria in primary cortical neurons","volume":"8","author":"Magalhaes","year":"2018","journal-title":"Sci Rep"},{"issue":"17","key":"10.1016\/j.slasd.2023.06.002_bib0030","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1056\/NEJMoa0901281","article-title":"Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease","volume":"361","author":"Sidransky","year":"2009","journal-title":"N Engl J Med"},{"issue":"29","key":"10.1016\/j.slasd.2023.06.002_bib0031","doi-asserted-by":"crossref","first-page":"7693","DOI":"10.1523\/JNEUROSCI.0628-16.2016","article-title":"Activation of beta-glucocerebrosidase reduces pathological alpha-synuclein and restores lysosomal function in Parkinson's patient midbrain neurons","volume":"36","author":"Mazzulli","year":"2016","journal-title":"J Neurosci"},{"issue":"4","key":"10.1016\/j.slasd.2023.06.002_bib0032","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1002\/acn3.177","article-title":"Progressive decline of glucocerebrosidase in aging and Parkinson's disease","volume":"2","author":"Rocha","year":"2015","journal-title":"Ann Clin Transl Neurol"},{"issue":"11","key":"10.1016\/j.slasd.2023.06.002_bib0033","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1002\/ajh.24877","article-title":"Outcomes after 18 months of eliglustat therapy in treatment-naive adults with Gaucher disease type 1: the phase 3 ENGAGE trial","volume":"92","author":"Mistry","year":"2017","journal-title":"Am J Hematol"},{"issue":"4","key":"10.1016\/j.slasd.2023.06.002_bib0034","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1002\/sctm.20-0302","article-title":"Synthetic mRNA-based differentiation method enables early detection of Parkinson's phenotypes in neurons derived from Gaucher disease-induced pluripotent stem cells","volume":"10","author":"Akiyama","year":"2021","journal-title":"Stem Cells Transl Med"}],"container-title":["SLAS Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2472555223000485?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2472555223000485?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T11:56:49Z","timestamp":1762862209000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2472555223000485"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":34,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["S2472555223000485"],"URL":"https:\/\/doi.org\/10.1016\/j.slasd.2023.06.002","relation":{},"ISSN":["2472-5552"],"issn-type":[{"value":"2472-5552","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel beta-glucocerebrosidase chaperone compounds identified from cell-based screening reduce pathologically accumulated glucosylsphingosine in iPS-derived neuronal cells","name":"articletitle","label":"Article Title"},{"value":"SLAS Discovery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.slasd.2023.06.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Inc. on behalf of Society for Laboratory Automation and Screening.","name":"copyright","label":"Copyright"}]}}